Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to -$1.7 million.

  • Anika Therapeutics' Cash from Investing Activities rose 4.63% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 78.50%. This contributed to the annual value of -$8.3 million for FY2024, which is 53.57% down from last year.
  • As of Q3 2025, Anika Therapeutics' Cash from Investing Activities stood at -$1.7 million, which was down 221.34% from -$539,000 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash from Investing Activities ranged from a high of $1.7 million in Q1 2021 and a low of -$3.4 million during Q2 2024.
  • Its 3-year average for Cash from Investing Activities is -$1.3 million, with a median of -$1.5 million in 2023.
  • Per our database at Business Quant, Anika Therapeutics' Cash from Investing Activities slumped by 176.47% in 2022 and then skyrocketed by 192.48% in 2025.
  • Over the past 5 years, Anika Therapeutics' Cash from Investing Activities (Quarterly) stood at -$1.2 million in 2021, then tumbled by 103.95% to -$2.5 million in 2022, then grew by 27.24% to -$1.8 million in 2023, then grew by 28.97% to -$1.3 million in 2024, then increased by 4.63% to -$1.7 million in 2025.
  • Its Cash from Investing Activities was -$1.7 million in Q3 2025, compared to -$539,000 in Q2 2025 and $1.7 million in Q1 2025.